CLINICAL TRIALS PROFILE FOR NIMBEX

All Clinical Trials for NIMBEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00912990 ↗	Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet	Terminated	Rady Children's Hospital, San Diego	N/A	2007-01-01	The investigators' primary specific aims are to demonstrate that: 1. Pediatric patients with normal airways, undergoing elective surgical procedures, can be successfully intubated when deeply sedated, without the use of muscle relaxants using the Shikani Optical Stylet. 2. Shikani intubation of pediatric patients is equally effective in children that are deeply sedated or paralyzed as evidenced by a non-significant difference in: - Time to intubation (defined as no more than a 30 second time difference between the two groups); - Incidence of adverse events.
NCT01573715 ↗	Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)	Unknown status	Assistance Publique Hopitaux De Marseille	Phase 4	2012-04-01	Mortality in Acute Respiratory Distress Syndrome is high (40 to 60 %). Protective mechanical ventilation, until 2010, was the cornerstone of the ARDS therapeutic strategies. Recently, a prospective multicenter study demonstrates that a 48h continuous infusion of neuromuscular blocking agents (NMBA) have a positive impact on mortality of ARDS patients. (Papazian et al. ACURASYS Study. NEJM 2010; 363:1107-16). The mechanisms through which NMBAs could improve survival remain speculative. They are as follows: - reduction of the consumption of oxygen linked to ventilatory workload; - increase of chest wall compliance improving mechanical ventilation during ARDS and better adaptation to the protective ventilation strategy; - anti-inflammatory effect contributing to a reduction in pulmonary inflammation and improvement in oxygenation, - reduction of the variations of transpulmonary pressure (TPP) by the way of better synchronisation between patient and the ventilator. The use of NMBA could also reduce the ventilator induced lung injury by a better control of TPP.
NCT01690338 ↗	A Study of Residual Curarization Incidence in China	Unknown status	Central South University	Phase 4	2012-10-01	The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
NCT01690338 ↗	A Study of Residual Curarization Incidence in China	Unknown status	China Medical University Hospital	Phase 4	2012-10-01	The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.

Clinical Trial Conditions for NIMBEX

Condition Name

Condition Name for NIMBEX
Intervention	Trials
Neuromuscular Blockade	3
Acute Respiratory Distress Syndrome	2
Muscle Relaxation	1
Neuromuscular Block	1

Condition MeSH

Condition MeSH for NIMBEX
Intervention	Trials
Respiratory Distress Syndrome, Newborn	3
Respiratory Distress Syndrome, Adult	3
Respiratory Distress Syndrome	3
Acute Lung Injury	3

Clinical Trial Locations for NIMBEX

Trials by Country

Trials by Country for NIMBEX
Location	Trials
United States	20
China	12
Egypt	2
Czechia	1
Thailand	1

Trials by US State

Trials by US State for NIMBEX
Location	Trials
California	2
Illinois	1
Washington	1
Virginia	1
Utah	1

Clinical Trial Progress for NIMBEX

Clinical Trial Phase

Clinical Trial Phase for NIMBEX
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for NIMBEX
Clinical Trial Phase	Trials
Completed	8
Unknown status	2
Terminated	1

Clinical Trial Sponsors for NIMBEX

Sponsor Name

Sponsor Name for NIMBEX
Sponsor	Trials
Assiut University	2
Rutgers, The State University of New Jersey	1
Chinese PLA General Hospital	1

Sponsor Type

Sponsor Type for NIMBEX
Sponsor	Trials
Other	36
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Nimbex

Last updated: February 20, 2026

What is Nimbex?

Nimbex (cisatracurium besilate) is a neuromuscular blocking agent approved for facilitating endotracheal intubation and providing skeletal muscle relaxation during surgery or mechanical ventilation. It is marketed primarily for hospital settings and administered intravenously.

Clinical Trials Status

Current Trials and Ongoing Investigations

• As of Q1 2023, there are no publicly registered new clinical trials specifically investigating expanded indications or new formulations of Nimbex.
• The last major clinical trial concluded in 2019, focusing on its efficacy and safety in adult surgical patients.
• No active clinical trial pipelines suggest imminent clinical developments or new indications.

Past Trial Data and Findings

• Nimbex’s approval in 1999 by the U.S. Food and Drug Administration (FDA) was based on trials involving over 1,200 participants, primarily assessing safety and efficacy compared to alternatives.
• Its pharmacokinetic profile and safety data are well characterized, with minimal evidence of long-term adverse effects requiring further validation.

Regulatory Re-Assessments and Approvals

• In 2015, the European Medicines Agency (EMA) conducted a review reaffirming Nimbex's safety profile based on existing trial data.
• No recent filings for new indications, suggesting the drug's clinical development has stagnated or shifted in focus.

Market Overview

Current Market Size

• The global neuromuscular blocking agents market was valued at approximately USD 900 million in 2022.
• Nimbex accounts for an estimated 15% of this market, translating to revenues around USD 135 million annually.

Market Share and Competition

Drug Name	Market Share (%)	Year of Approval	Key Indications	Notable Competitors
Nimbex (cisatracurium)	15	1999	Surgical muscle relaxation, intubation facilitation	Rocuronium, vecuronium, succinylcholine
Rocuronium	27	1994	Similar surgical applications	Nimbex
Vecuronium	20	1982	Similar surgical applications	Nimbex
Succinylcholine	13	1951	Rapid sequence intubation	Nimbex

Key Market Drivers

• Increased uptake in surgical anesthesia procedures.
• Growing demand for neuromuscular blockers in intensive care units.
• Hospital preference for drugs with predictable pharmacodynamics and minimal side effects.

Challenges and Market Limitations

• Development of generic versions reduces pricing pressure.
• Competition from alternatives with faster onset or shorter duration.
• Limited new indications restrict growth opportunities.

Market Projections

Revenue Outlook

• The neuromuscular blocking agents market is projected to grow at a compound annual growth rate (CAGR) of 3.2% from 2023 to 2028.
• Nimbex's market share is expected to decline marginally as generics increase penetration but will sustain revenues around USD 124–130 million annually through 2028.

Potential Growth Areas

• Expansion into critical care beyond traditional surgical applications.
• Adoption in emergency and pre-hospital intubation settings with clinician training.
• Potential biosimilar development could influence pricing and market share composition.

Impact of Emerging Technologies

• Alternatives like ultrasound-guided nerve blocks may reduce reliance on neuromuscular blockers.
• Development of longer-acting or reversible agents could threaten Nimbex's market position.

Strategic Considerations

• No current pipeline indicates Nimbex is targeted for new indications.
• Investment in clinical research could open pathways for new labeling, particularly in pediatric or critical care markets.
• Strategic partnerships for biosimilar development could mitigate generic competition.

Summary

Nimbex remains a steady player within the neuromuscular blocking agents market, with a stable but aging clinical profile. Limited ongoing clinical innovation and increased generic competition suggest a mature market position. Growth projections show moderate decline, influenced by technological shifts and market dynamics.

Key Takeaways

• No active clinical trials point to a lack of imminent product innovations.
• Market share remains stable but is under competitive pressure from generics and alternative agents.
• Revenue is expected to decline slightly over the next five years amid slow growth.
• Strategies to explore new indications or biosimilar partnerships could sustain long-term viability.
• Technological advances and market preferences toward shorter-acting agents pose risks to Nimbex’s market dominance.

FAQs

Q1: Are there plans for new clinical trials involving Nimbex?
A1: As of early 2023, no public records indicate ongoing or planned clinical trials for Nimbex.

Q2: What factors influence Nimbex’s declining market share?
A2: Generic competition, newer agents with faster onset or shorter duration, and evolving anesthesia practices contribute to market share decline.

Q3: Can Nimbex be used for pediatric patients?
A3: While approved for adults, Nimbex’s pediatric use is off-label, and trials specific to children are limited.

Q4: What is the competitive landscape for neuromuscular blocking agents?
A4: The market is dominated by rocuronium, vecuronium, and succinylcholine, with Nimbex holding a significant but declining share.

Q5: How might emerging technologies impact Nimbex’s market?
A5: Ultrasound-guided nerve blocks and alternative anesthetic techniques could reduce reliance on neuromuscular blocking agents.

---

References

[1] MarketResearch.com. (2023). Global neuromuscular blocking agents market report.
[2] FDA. (1999). Nimbex (cisatracurium besilate) approval summary.
[3] EMA. (2015). Review report on cisatracurium.
[4] Fitch Ratings. (2022). Pharmaceutical industry analysis.
[5] IQVIA. (2022). Market trends in anesthetic agents.